Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05229991




Registration number
NCT05229991
Ethics application status
Date submitted
27/01/2022
Date registered
8/02/2022
Date last updated
6/05/2023

Titles & IDs
Public title
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
Scientific title
Once Daily (QD) Dosing of Lonafarnib (LNF) Co-administered With Ritonavir (RTV) for Treatment of Chronic Hepatitis D Virus Infection
Secondary ID [1] 0 0
SCRC20042
Secondary ID [2] 0 0
SOR-0527-20-CTIL
Universal Trial Number (UTN)
Trial acronym
LOWR6
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis D, Chronic 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Lonafarnib
Treatment: Drugs - Ritonavir

Experimental: Intervention Group - Lonafarnib 50mg co-administered with ritonavir 200 mg


Treatment: Drugs: Lonafarnib
once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.

Treatment: Drugs: Ritonavir
once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Viral load change
Timepoint [1] 0 0
48 weeks
Primary outcome [2] 0 0
Viral load change
Timepoint [2] 0 0
72 weeks
Secondary outcome [1] 0 0
HDV RNA levels below LLOQ
Timepoint [1] 0 0
72 weeks
Secondary outcome [2] 0 0
Viral load change
Timepoint [2] 0 0
24 weeks

Eligibility
Key inclusion criteria
1. Chronic HDV infection, with compensated liver disease, documented by a positive HDV
antibody (Ab) test and HDV RNA by quantitative polymerase chain reaction (qPCR) assay,
prior to initiation of trial treatment.

2. Demonstrable suppression of HBV DNA (< 100 IU/mL) following anti-HBV nucleos(t)ide
treatment prior to initiating trial therapy.

3. Willing and able to comply with trial procedures and provide written informed consent.

4. ALT > ULN documented on at least one occasion during the 12 months preceding
enrollment to the trial.

5. Male and female participants who are 18 years of age or above.

6. ECGs demonstrating no acute ischemia or clinically significant (CS) abnormality and a
corrected QT interval by Fridericia correction formula (QTcF) < 450 ms in males and
<470 ms in females.

7. Sexually active female patients of childbearing potential and sexually active male
patients with partners of childbearing potential must agree to use adequate methods of
contraception during the trial. Females of childbearing potential are all those except
women who are surgically sterile, who have medically documented ovarian failure, or
who are at least 1 year postmenopausal.

For female patients:

- Progestin-based hormonal contraception (implant, injection, oral) associated with
inhibition of ovulation for = 3 months before screening. Use of a progestin-based
implant or injection method requires the additional use of a barrier method (use of
condom [male partner] or diaphragm with spermicide or cervical cap with spermicide)
from screening. Use of a progestin-only, oral method requires the additional use of
double barrier methods (use of condom [male partner] with either diaphragm with
spermicide or cervical cap with spermicide) from screening, or

- Intrauterine device (IUD) or intrauterine system (IUS) in place = 3 months before
screening AND a barrier method (use of condom [male partner] or diaphragm with
spermicide or cervical cap with spermicide) from screening, or

- Surgical sterilization of the partner (vasectomy = 1 month before screening) AND a
barrier method (use of condom [male partner] or diaphragm with spermicide or cervical
cap with spermicide) from screening, or

- Double-barrier methods (use of condom [male partner] with either diaphragm with
spermicide or cervical cap with spermicide) from screening.

For male patients:

- Surgical sterilization (vasectomy = 1 month before screening) AND a barrier method
(use of condom or diaphragm with spermicide or cervical cap with spermicide) from
screening, or

- Consistently and correctly use a condom from screening AND female partner must agree
to use a hormonal contraceptive, a nonhormonal non-barrier method (eg, copper IUD), or
a nonhormonal barrier method (eg, diaphragm with spermicide or cervical cap with
spermicide).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Participation in a clinical trial with, or use of, any investigational agent within 30
days or 5 half-lives, whichever is longer, before starting LNF treatment.

2. Female patients who are pregnant or breastfeeding. Female patients must have a
negative serum test at screening and a negative urine pregnancy test (minimum
sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [hCG] at
baseline, within 24 hours prior to the start of any investigational agent). Male
patients with female sexual partners who are pregnant.

3. Current or previous history of decompensated liver disease (e.g. variceal bleeding,
ascites, hepatic encephalopathy, hepatorenal syndrome).

4. Platelet count < 70,000 cells/mm3; white blood cell (WBC) < 3,000 cells / mm3

5. Creatinine clearance (< 30 mL/min by Cockroft-Gault).

6. Co-infected with human immunodeficiency virus (HIV) or hepatitis C virus (HCV).
Patients with a positive HCV Ab at baseline are allowed if they have completed a
curative antiviral regimen and have documented undetectable HCV RNA 12 weeks or more
following last dose of anti-HCV medications.

7. Abnormal thyroid-stimulating hormone (TSH) or free thyroxine (fT4) levels. Patients
with well-controlled thyroid function or TFTs that are not clinically significant may
be enrolled.

8. Evidence of another form of viral hepatitis or another form of liver disease (eg,
autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis,
Wilson's disease, alcoholic liver disease, nonalcoholic steatohepatitis,
hemochromatosis, alpha 1 anti-trypsin deficiency).

9. History of hepatocellular carcinoma.

10. Retinal disorder or clinically relevant ophthalmic disorder

11. Any malignancy within 5 preceding years. Exceptions are malignancies surgically
excised with curative intent and/or evidence of being disease free for at least 5
years (eg, breast ductal carcinoma in situ [DCIS] or squamous/basal cell skin cancer
treated with curative intent), or successfully treated in-situ carcinoma of the cervix

12. Other significant medical condition that may require intervention during the trial.

13. Any condition that may impact proper absorption (eg, short bowel syndrome,
inflammatory bowel disease, atrophic gastritis, partial gastrectomy) should be
discussed with the Medical Monitor.

14. Consumption of grapefruit, Seville oranges, or product that contains grapefruit or
Seville oranges.

15. Use of heparin or warfarin during the trial.

16. Long-term treatment (> 2 weeks) before or during the trial with agents that have a
high risk for nephrotoxicity or hepatotoxicity.

1. Concomitant use (within 2 weeks of Day 1 and throughout trial conduct) of any
medications (prescription, OTC, herbal products) or foods as follows:

2. Known potent inhibitors of CYP3A, including statins (with the exception of
pravastatin and fluvastatin);

3. Known potent inducers of CYP3A or CYP3A sensitive substrates;

4. Known CYP2C19 and P-gp sensitive substrates with a narrow therapeutic index -
refer to the Concomitant Medication Manual for additional instructions;

5. Known sensitive substrates of OCT1 with a narrow therapeutic index; and

6. Drugs known to prolong the PR or QT interval unless otherwise described in this
protocol.

17. Concomitant use of medications contraindicated in the prescribing information for RTV.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/05/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/04/2025
Actual
Sample size
Target
30
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Israel
State/province [1] 0 0
Be'er Sheva
Country [2] 0 0
New Zealand
State/province [2] 0 0
Auckland
Country [3] 0 0
Turkey
State/province [3] 0 0
Istanbul

Funding & Sponsors
Primary sponsor type
Other
Name
Soroka University Medical Center
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Eiger BioPharmaceuticals
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Open label, single arm, multi-center clinical trial of lonafarnib 50 mg QD plus ritonavir 200
mg QD, administered orally, over a 48-week treatment period, with a 24-week post-treatment
follow-up period, in patients with chronic Hepatitis D Virusinfection.

Objectives: To evaluate the safety and tolerability of once daily dosing of lonafarnib 50 mg
with ritonavir 200 mg over a 48-week treatment period.

To evaluate the effect of once daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a
48-week treatment period with a 24-week post-treatment follow-up on HDV viral levels.

Trial population: Up to 30 patients with chronic HDV infection with detectable HDV RNA and
compensated liver disease.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05229991
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Ohad Etzion, MD
Address 0 0
Soroka University Medical Center
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries